Idelalisib

CAS: 870281-82-6

Ref. 3D-FI29231

Informação sobre produto

• Nome: Idelalisib
• Sinónimos: (S)-2-(1-(1-(9H-Purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneCAL-101GS-1101, (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-, 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-, 5-Fluoro-3-Phenyl-2-[(1S)-1-(9H-Purin-6-Ylamino)Propyl]-4(3H)-Quinazolinone, Cal-101, Delalisib, Gs-1101, N⁶-[(S)-1-(5-Fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl]adenine, Zydelig

Descrição

Idelalisib is a drug that inhibits the phosphorylation of c-Jun and the activation of AP-1. Idelalisib has been shown to be effective in vitro against bowel disease, allergic symptoms, and cellular transformation. In vivo experiments have shown that idelalisib can reduce tumor size in mice with histiocytic lymphoma. Idelalisib is also known to be a potent inhibitor of the JAK2/STAT3 pathway, which has been implicated in many diseases such as rheumatoid arthritis, inflammatory bowel disease, and myelodysplastic syndromes. The matrix effect may be a side effect of this drug as it may lead to gastrointestinal perforation or hemorrhage.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 415.42 g/mol
• Fórmula: C₂₂H₁₈FN₇O
• Pureza: Min. 95%
• Cor/forma: Powder